Press Release

01.03.2011

EU funding assigned to Prolifica project

Xeptagen gets a grant from EU FPVII to participate in the Prolifica consortium aiming to reveal novel aetiological factors for HCC, identify and evaluate biomarkers and demonstrate the efficacy of selective antiviral therapy to prevent HCC.